Beam Therapeutics BEAM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $288.29M-45.4% | $294.94M+4.6% | $267.96M+16.4% | $282.13M-3.6% | $527.91M+83.4% | ||
| $923.36M+33.4% | $950.27M+67.1% | $807.01M+16.0% | $868.21M+21.4% | $692.05M-14.2% | ||
| $1.27B+1.6% | $1.27B+44.5% | $1.1B+16.2% | $1.18B+14.2% | $1.25B+11.2% | ||
| $101.25M-7.6% | $104.5M-6.2% | $108.29M-4.6% | $108.82M-7.4% | $109.57M-9.4% | ||
| $1.48B+0.9% | $1.48B+34.2% | $1.31B+11.9% | $1.39B+10.3% | $1.47B+7.9% | ||
| $12.29M+59.6% | $10.23M+164% | $9.55M+150% | $10.56M+138% | $7.7M+176% | ||
| $304K-99.6% | $6.66M-93.9% | $110.32M+23.5% | $105.82M+24.6% | $85.2M+18.2% | ||
| $74.57M-47.3% | $96.94M-46.8% | $182.56M+9.8% | $174.13M-1.8% | $141.55M-24.4% | ||
| $100.19M— | —— | —— | —— | —— | ||
| $316.36M-8.0% | $242.82M-34.4% | $345.08M-9.2% | $344.34M-15.4% | $343.78M-23.0% | ||
| $1.03M+2.1% | $1.02M+21.7% | $1.01M+22.8% | $1.01M+22.3% | $1.01M+22.2% | ||
| -$1.74B-3.6% | -$1.64B-4.8% | -$1.89B-28.1% | -$1.78B-28.9% | -$1.68B-30.1% | ||
| $1.16B+3.1% | $1.24B+68.8% | $966M+22.1% | $1.05B+22.6% | $1.13B+23.6% | ||
| $1.48B+0.9% | $1.48B+34.2% | $1.31B+11.9% | $1.39B+10.3% | $1.47B+7.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Beam Therapeutics cover its short-term obligations?
- Its current ratio is 16.99 — current assets exceed current liabilities.
- Where does Beam Therapeutics's balance sheet data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.